Successful public offering of TME Pharma NV

TME Pharma NV announced the successful completion of its public offering for a gross amount of EUR 2.6 million. This operation resulted in the issuance of 52 million new ordinary shares. Existing shareholders subscribed to 77.52% of this offering, for a total of EUR 2,015,549.10. The remainder of the offering was covered by underwriters. The company plans to use these funds to expand its financial visibility, through research, development and strategic transactions, until June 2025.

The lead product, NOX-A12, has shown improved survival in brain cancer patients treated with a combination of therapies. This product benefits from preferred regulatory statuses in the United States and Europe, such as Fast-Track status. TME Pharma is preparing strategic transactions for its NOX-A12 and NOX-E36 programs.